Affiliated Hospital To Academy Of Military Medical Sciences
Clinical trials sponsored by Affiliated Hospital To Academy Of Military Medical Sciences, explained in plain language.
-
Nanobody-Powered CAR-Ts take on tough lymphoma
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy that uses tiny antibodies (nanobodies) to target two markers on cancer cells (CD19 and CD20). The goal is to see if it is safe and to find the best dose for people with B-cell lymphoma that has come back or not respond…
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat plasma cell cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main…
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC